ND-L02-s0201

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

113 competitors in Fibrosis

#DrugCompanyPhaseTrials

1

Gleevec

Novartis

Phase 3

32

PEG-Intron

Merck & Co.

Phase 3

23

Atacand

AstraZeneca

Phase 3

14

Esbriet

LLegacy Health System

Phase 3

55

Ofev

Boehringer Ingelheim

Phase 3

26

Ocaliva

IIntercept Pharmaceuticals

Phase 3

17

Myfortic

Novartis

Phase 3

18

Ozempic

Novo Nordisk

Phase 2

19

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

210

Pegozafermin

89bio

Phase 3

—Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Double-blind1 trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

Completed·Bristol-Myers Squibb·Phase 1·NCT01858935·56 enrolled

Fibrosis1 trial

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Completed·Bristol-Myers Squibb·Phase 1·NCT02227459·25 enrolled

Phase 21 trial

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

Completed·NNitto Denko Corporation·Phase 2·NCT03538301·123 enrolled

Unspecified1 trial

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

Completed·Bristol-Myers Squibb·Phase 1·NCT03241264·12 enrolled

Details

Drug Info

Related News